Investment and layout of artificial intelligence have become an important part of the competition of pharmaceutical giants

【Pharma Network Industry News】New drug research and development has always been one of the most risky and complex and time-consuming technical research fields in the field of
human scientific research.
According to statistics, the overall cost of a new drug is about 2.
6 billion US dollars, which takes about 10 years and has a success rate of less than one-tenth
.
Therefore, in order to improve R&D efficiency and reduce R&D investment, with the continuous development of science and technology in recent years, more and more companies and researchers have begun to apply "artificial intelligence" to pharmaceutical R&D and market, trying to further improve the success rate of new drug research and development through artificial intelligence technology AI algorithms, reduce manufacturing costs and R&D time
.
On October 18, GSK announced an expanded three-year collaboration agreement with U.
S.
precision medicine company Tempus, under which GSK will have access to Tempus' artificial intelligence platform, including data
that identifies patients and their situations.
Through Tempus' AI and machine learning capabilities, GSK will work with Tempus to improve clinical trial design, accelerate enrollment, and identify drug targets
.
This will help GSKLINE R&D success rates and deliver more personalized treatments
to patients faster.
With the help of artificial intelligence and artificial intelligence to accelerate innovation and research and development, it is not surprising
in the pharmaceutical track.
Since 2022, a number of domestic and foreign pharmaceutical companies have announced that they will cooperate with technology companies and artificial intelligence platforms to accelerate their entry into the field of AI drug research and development
.
On July 23 this year, Yunnan Baiyao and Huawei Technologies Co.
, Ltd.
signed the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D" in Fuzhou City,
Fujian Province.
According to the agreement, Yunnan Baiyao and Huawei Technologies will carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, explore mechanisms for joint scientific research and innovation, and expand the breadth and depth
of cooperation between the two sides.
Specifically, the two parties will cooperate
in many aspects such as large and small molecule design, related diseases, and database development.
It is understood that Huawei has quite strong technical strength
in the field of artificial intelligence.
Huawei Technologies Co.
, Ltd.
has rich experience
in AI-assisted drug development, cloud computing, and artificial intelligence.
The cooperation between the two parties is expected to jointly promote the deep integration of artificial intelligence technology and the big health industry market, and build a big health industry ecosystem
.
In June, Hisun Pharmaceutical and XtalPi, a drug R&D technology company driven by intelligent and automated technology, also joined hands again, further expanding the cooperation
between the two parties in the field of chemical synthesis.
It is reported that XtalPi has an automated experimental technology platform and a compound management platform, which can provide flexible intelligent chemical synthesis services, which will continue to help Hisun Pharmaceutical explore drug synthesis pathways and methods with higher efficiency and accelerate the drug research and development process
.
At the beginning of this year, the two sides launched their first chemical synthesis project
.
In April, PathAI and GlaxoSmithKline (GSK) jointly announced a multi-year strategic R&D collaboration to leverage PathAI's digital pathology technology platform, including its AIM-NASH tool, to accelerate scientific research and drug development in
oncology and nonalcoholic steatohepatitis (NASH).
。 .
.
.
.
.
.
In general, artificial intelligence has become a popular investment track for enterprises in the pharmaceutical and medical industry, and a large number of pharmaceuticals are trying to make more beneficial attempts
in reducing costs, shortening research and development cycles, and reducing risks by investing in artificial intelligence companies and cooperating with artificial intelligence companies.
Industry analysts believe that the future investment and layout of artificial intelligence is expected to become an important part
of the competition of pharmaceutical giants.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.